C12N 2510/00
Genetically modified cells
C12N2510/00 (Genetically modified cells) appears on 4,188 US grants and 9,675 published applications in this corpus.
Search patents in C12N- Granted patents
- 4,188
- Published applications
- 9,675
- Assignees
- 2,914
- Inventors
- 16,618
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 2 | 0 |
| 1986 | 1 | 0 |
| 1987 | 5 | 0 |
| 1988 | 1 | 0 |
| 1989 | 5 | 0 |
| 1990 | 5 | 0 |
| 1991 | 6 | 0 |
| 1992 | 5 | 0 |
| 1993 | 11 | 0 |
| 1994 | 9 | 0 |
| 1995 | 15 | 0 |
| 1996 | 26 | 0 |
| 1997 | 45 | 0 |
| 1998 | 67 | 0 |
| 1999 | 58 | 0 |
| 2000 | 53 | 0 |
| 2001 | 61 | 34 |
| 2002 | 61 | 175 |
| 2003 | 61 | 215 |
| 2004 | 44 | 152 |
| 2005 | 57 | 185 |
| 2006 | 69 | 152 |
| 2007 | 61 | 166 |
| 2008 | 58 | 137 |
| 2009 | 62 | 182 |
| 2010 | 77 | 181 |
| 2011 | 77 | 171 |
| 2012 | 106 | 186 |
| 2013 | 90 | 175 |
| 2014 | 113 | 194 |
| 2015 | 162 | 217 |
| 2016 | 172 | 298 |
| 2017 | 144 | 401 |
| 2018 | 176 | 437 |
| 2019 | 222 | 492 |
| 2020 | 254 | 620 |
| 2021 | 252 | 686 |
| 2022 | 260 | 834 |
| 2023 | 275 | 770 |
| 2024 | 321 | 952 |
| 2025 | 363 | 933 |
| 2026 | 274 | 730 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Inducible chimeric antigen receptor and application thereof6 Oct 2026US 12,752,007 B2Beijing Tiantan Hospital, Capital Medical University
- Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy6 Oct 2026US 12,753,220 B2Cellectis
- Fas-associated factor 1 (FAF1)-loaded exosomes and use thereof as anti-cancer agent29 Sep 2026US 12,746,271 B2Kainos Medicine, Inc.
- Anti-CD123 antibodies, anti-CD123 chimeric antigen receptors and anti-CD123 chimeric antigen receptors T cells29 Sep 2026US 12,747,295 B2Centre Hospitalier Regional Universitaire De Besancon
- Composition for inducing immunotolerance8 Oct 2026US 2026/0306540 A1
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Chimeric receptors8 Oct 2026US 2026/0306631 A1St. Jude Children?S Research Hospital
- Process for purifying red blood cell membrane fragments8 Oct 2026US 2026/0306656 A1Ohio State Innovation Foundation
- Application of stem cells or transgenic stem cells8 Oct 2026US 2026/0306716 A1Anhui Longhui Stem Cell Biotechnology Co., Ltd
Most cited
By later US patents
- Implantable biocompatable immunoisolatory vehicle for delivery of selected therapeutic products448US 6,083,523 ABrown University · 2000
- Production of a multimeric protein by cell fusion method411US 5,916,771 AAbgenix, Inc. · 1999
- System for diagnosis and treatment of wounds390US 5,152,757 AThe Brigham and Women S Hospital, Inc. · 1992
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies343US 6,410,319 B1City of Hope · 2002